MediGene launches clinical phase IIa trial of arthritis drug RhuDex |
|
|
|
Published
:
Tue, 23 Jan 2007 11:17
|
MARTINSRIED, Germany (AFX) - MediGene AG said it has launched a clinical phase IIa trial for rheumatoid arthritis drug RhuDex.Results for the trial on 35 people are expected in the second half of 2007.This will be followed by a full phase II trial on 200 people in 2008, said the biotech company in a statement.'With the start of this clinical study, we have reached a very important milestone on the road to opening up the market potential of this drug candidate,' said CEO Peter Heinrich.RhuDex was added to MediGene's clinical portfolio as part of its acquisition of Avidex Ltd in 2006.krysia.diver@afxnews.comkd/jfrCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Penwest begins safety test of painkiller 